Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease

Clinical and Experimental Immunology

Volumn 184, Issue 2, 2016, Pages 159-173

  Boutet, M A ^a,b   Bart, G ^a,b,c   Penhoat, M ^a,b,c   Amiaud, J ^a,b   Brulin, B ^a,b   Charrier, C ^a,b   Morel, F ^d   Lecron, J C ^d,e   Rolli Derkinderen, M ^f   Bourreille, A ^c,f   Vigne, S ^g   Gabay, C ^g   Palmer, G ^g   Le Goff, B ^a,b,c   Blanchard, F ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE POITIERS   (France)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Crohn's disease; IL 36; psoriasis; rheumatoid arthritis

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; IMIQUIMOD; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 36 RECEPTOR ANTAGONIST; INTERLEUKIN 36ALPHA; INTERLEUKIN 36BETA; INTERLEUKIN 36GAMMA; INTERLEUKIN 38; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; EXPERIMENTAL DERMATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LANGERHANS CELL; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PLASMA CELL; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; TH17 CELL;

EID: 84983301710     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12761     Document Type: Article

References (45)

1. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013; 39:1003–18.
2. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6:232–41.
3. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol 2015; 97:645–52.
4. Vigne S, Palmer G, Martin P et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood 2012; 120:3478–87.
5. Gunther S, Sundberg EJ. Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol 2014; 193:921–30.
6. van de Veerdonk FL, Stoeckman AK, Wu G et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci USA 2012; 109:3001–5.
7. Tortola L, Rosenwald E, Abel B et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 2012; 122:3965–76.
8. Johnston A, Xing X, Guzman AM et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 2011; 186:2613–22.
9. Bachmann M, Scheiermann P, Hardle L, Pfeilschifter J, Muhl H. IL-36gamma/IL-1F9, an innate T-bet target in myeloid cells. J Biol Chem 2012; 287:41684–96.
10. Carrier Y, Ma HL, Ramon HE et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 2011; 131:2428–37.
11. Lian LH, Milora KA, Manupipatpong KK, Jensen LE. The double-stranded RNA analogue polyinosinic–polycytidylic acid induces keratinocyte pyroptosis and release of IL-36gamma. J Invest Dermatol 2012; 132:1346–53.
12. Gresnigt MS, Rosler B, Jacobs CW et al. The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol 2013; 43:416–26.
13. Towne JE, Renshaw BR, Douangpanya J et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem 2011; 286:42594–602.
14. Ramadas RA, Ewart SL, Medoff BD, LeVine AM. Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol 2011; 44:134–45.
15. Segueni N, Vigne S, Palmer G et al. Limited contribution of IL-36 versus IL-1 and TNF pathways in host response to mycobacterial infection. PLOS ONE 2015; 10:e0126058.
16. Ichii O, Otsuka S, Sasaki N et al. Local overexpression of interleukin-1 family, member 6 relates to the development of tubulointerstitial lesions. Lab Invest 2010; 90:459–75.
17. Scheiermann P, Bachmann M, Hardle L et al. Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury. Sci Rep 2015; 5:8521.
18. Ciccia F, Accardo-Palumbo A, Alessandro R et al. IL-36alpha axis is modulated in patients with primary Sjogren's syndrome. Clin Exp Immunol 2015; 181:230–8.
19. Frey S, Derer A, Messbacher ME et al. The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis 2012; 72:1569–74.
20. Magne D, Palmer G, Barton JL et al. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 2006; 8:R80.
21. Lamacchia C, Palmer G, Rodriguez E et al. The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthritis Res Ther 2013; 15:R38.
22. Derer A, Groetsch B, Harre U et al. Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis. PLOS ONE 2014; 9:e101954.
23. van der Fits L, Mourits S, Voerman JS et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182:5836–45.
24. Rabeony H, Pohin M, Vasseur P et al. IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome. Eur J Immunol 2015; 45:2847–57.
25. Le Goff B, Soltner E, Charrier C et al. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther 2009; 11:R185.
26. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580–8.
27. Altman R, Asch E, Bloch D et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039–49.
28. Krenn V, Morawietz L, Haupl T, Neidel J, Petersen I, Konig A. Grading of chronic synovitis – a histopathological grading system for molecular and diagnostic pathology. Pathol Res Pract 2002; 198:317–25.
29. Jarry A, Bossard C, Droy-Dupre L et al. Heterogeneity of subordination of the IL-18/IFN-gamma axis to caspase-1 among patients with Crohn's disease. Lab Invest 2015; 95:1207–17.
30. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005; 174:3695–702.
31. Darrieutort-Laffite C, Boutet MA, Chatelais M et al. IL-1beta and TNFalpha promote monocyte viability through the induction of GM-CSF expression by rheumatoid arthritis synovial fibroblasts. Mediators Inflamm 2014; 2014:241840.
32. Guihard P, Danger Y, Brounais B et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells 2012; 30:762–72.
33. Duplomb L, Baud'huin M, Charrier C et al. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 2008; 149:3688–97.
34. Rabeony H, Petit-Paris I, Garnier J et al. Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1alpha, TNFalpha and oncostatin M. PLOS ONE 2014; 9:e101937.
35. Guihard P, Boutet MA, Brounais-Le Royer B et al. Oncostatin M, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury. Am J Pathol 2015; 185:765–75.
36. Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 2014; 19:822–4.
37. Milora KA, Fu H, Dubaz O, Jensen LE. Unprocessed interleukin-36alpha regulates psoriasis-like skin inflammation in cooperation with interleukin-1. J Invest Dermatol 2015; 135:2992–3000.
38. Catana CS, Berindan Neagoe I, Cozma V, Magdas C, Tabaran F, Dumitrascu DL. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2015; 21:5823–30.
39. Lopetuso LR, Chowdhry S, Pizarro TT. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol 2013; 4:181.
40. Friedrich M, Tillack C, Wollenberg A, Schauber J, Brand S. IL-36gamma sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. Inflamm Bowel Dis 2014; 20:1891–901.
41. Medina-Contreras O, Harusato A, Nishio H et al. Cutting edge: IL-36 receptor promotes resolution of intestinal damage. J Immunol 2016; 196:34–8.
42. Li N, Yamasaki K, Saito R et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36gamma induction in human epidermal keratinocytes. J Immunol 2014; 193:5140–8.
43. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932–6.
44. Vigne S, Palmer G, Lamacchia C et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood 2011; 118:5813–23.
45. Nerlich A, Ruangkiattikul N, Laarmann K et al. C/EBPbeta is a transcriptional key regulator of IL-36alpha in murine macrophages. Biochim Biophys Acta 2015; 1849:966–78.